Nasus Pharma LTD

Eyal Rubin, Chief Financial Officer of Nasus Pharma Ltd, reported multiple transactions in common stock on September 18, 2026.

Dan Benjamin Teleman, Chief Executive Officer and a Director of Nasus Pharma Ltd, reported multiple transactions in common stock on July 22, 2026.

CEO Dan Benjamin Teleman purchased 2,900 ordinary shares of Nasus Pharma Ltd at $3.76 per share, signaling executive confidence.

Nasus Pharma Ltd's CEO, Dan Benjamin Teleman, acquired 15,000 ordinary shares at $2.04 each, increasing his direct beneficial ownership.

Balyasny Asset Management L.P. and affiliated entities have disclosed beneficial ownership of 9.99% of Nasus Pharma Ltd.'s common stock.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 9.99% of Nasus Pharma Ltd.'s common stock.

Funicular Funds, LP and Cable Car Capital, LP, along with Jacob Ma-Weaver, have collectively acquired a 5.2% stake in Nasus Pharma Ltd.

Dr. Ronnie Hershman and Hershman Holdings LLC reported a combined beneficial ownership of 15.3% in Nasus Pharma Ltd. as of September 30, 2025.

Dr. Dalia Megiddo has reported beneficial ownership of 20.9% of Nasus Pharma Ltd.'s ordinary shares as of September 30, 2025.

Udi Gilboa has reported beneficial ownership of 21.1% of Nasus Pharma Ltd.'s ordinary shares as of September 30, 2025.